Minocyclin

Phase 2Small molecule

UUniversity of Southern California

Minocyclin is one of 27 small molecule programs targeting Subarachnoid Hemorrhage. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Subarachnoid HemorrhageActive, not recruiting

Subarachnoid HemorrhagePhase 2

Active, not recruiting

Competition

Competitive Landscape

34 competitors in Subarachnoid Hemorrhage

#DrugCompanyPhaseTrials

Keppra

UCB

Approved

1 2

Cardene

Sun Pharmaceutical Industries, Inc.

Approved

1 3

Olumiant

Pletal

2 5

Xylocaine

MMEDRx USA, Inc.

Approved

2 6

Neurontin

VViatris Specialty LLC

Approved

1 7

Heparin Sodium

BBaxter Healthcare Corporation

Approved

—8

Ketalar

AAultman Health Foundation

Approved

—9

Angiomax

BBaxter Healthcare Corporation

Marcaine

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q4 2028

Phase 2Active, not recruiting

Subarachnoid Hemorrhage

NCT04876638

Clinical

Trials by Indication[1]

Ischemic stroke1 trial

Minocycline Efficacy in Improving Neurological Outcome of Patients Who Undergo Endovascular Revascularization for Acute Ischemic Stroke

Withdrawn·SState University of New York at Buffalo·Phase 2·NCT05367362

Subarachnoid Hemorrhage1 trial

Minocycline for Aneurysmal Subarachnoid Hemorrhage (MASH)

Active, not recruiting·UUniversity of Southern California·Phase 2·NCT04876638·20 enrolled

Major Depressive Disorder1 trial

INflammation-based Stratification for Immune-Targeted Augmentation in Major Depressive Disorder

Recruiting·UUniversiteit Antwerpen·Phase 3·NCT05644301·240 enrolled

Sources

References

[1]
ClinicalTrials.gov — 3 trial records for Minocyclin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Minocyclin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Minocyclin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — University of Southern California company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: UUniversity of Southern California

Minocyclin

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q4 2028

Trials by Indication[1]

Ischemic stroke1 trial

Subarachnoid Hemorrhage1 trial

Major Depressive Disorder1 trial

References

Drug Info

Quick Facts

Related News